文献速递治疗药物监测与药物基因组学特殊人群用药

两种容积吸收微采样装置用于免疫抑制居家治疗药物监测的临床验证

Clinical validation of two volumetric absorptive microsampling devices to support home-based therapeutic drug monitoring of immunosuppression.
PubMed 文献 · Br J Clin Pharmacol · 2024-07-25

该研究在25例肾移植受者中比较上臂Tasso-M20与指尖Mitra两种VAMS装置与静脉采血的一致性,他克莫司全血浓度偏差在±20%内的样本分别占86%和88%,霉酚酸血清浓度经预设校正因子后分别占84%和76%,患者偏好Tasso-M20。

要点

  • 他克莫司VAMS与静脉采血一致性:上臂86%、指尖88%样本偏差在±20%内。
  • 霉酚酸经校正因子后:上臂84%、指尖76%样本偏差在±20%内。
  • 患者支持居家监测,偏好上臂Tasso-M20装置。

核心结论

  • 两种常用VAMS装置分析性能相似,可用于他克莫司和霉酚酸的临床监测。
  • 患者支持居家监测并偏好Tasso-M20上臂装置。

研究设计与样本

  • 临床验证研究,纳入25例肾移植受者,采集50对VAMS与静脉采血配对样本。
  • 采用Passing-Bablok回归和Bland-Altman分析比较两种VAMS装置(上臂Tasso-M20和指尖Mitra)与静脉采血样本。
  • 使用预先定义的公式和固定校正因子将霉酚酸VAMS浓度转换为血清浓度。
  • 通过既定问卷评估患者使用性、可接受性和可行性。

主要发现

  • 他克莫司全血浓度偏差在±20%内的样本:上臂86%、指尖88%。
  • 霉酚酸采用校正因子(上臂1.3、指尖1.47)后,偏差在±20%内的样本:上臂84%、指尖76%。
  • 患者体验调查显示上臂装置疼痛有限且使用性可接受。

关键数值与推荐

  • 他克莫司全血浓度偏差在±20%内的样本比例:上臂86%、指尖88%。
  • 霉酚酸血清浓度偏差在±20%内的样本比例:上臂84%、指尖76%(使用校正因子1.3和1.47)。

临床怎么用

  • 可考虑采用VAMS装置进行他克莫司和霉酚酸的居家治疗药物监测。
  • 霉酚酸VAMS结果需按预设校正因子(上臂1.3、指尖1.47)转换为血清浓度。
  • 患者偏好上臂Tasso-M20装置,可优先考虑。

局限性

  • 样本量较小(25例肾移植受者)。
  • 仅验证了他克莫司和霉酚酸两种药物。
  • 霉酚酸校正因子为预先定义,需进一步外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Dried blood volumetric absorptive microsamples (VAMS) may facilitate home-based sampling to enhance therapeutic drug monitoring after transplantation. This study aimed to clinically validate a liquid chromatography-tandem mass spectrometry assay using 2 VAMS devices with different sampling locations (Tasso-M20 for the upper arm and Mitra for the finger). Patient preferences were also evaluated. METHODS: Clinical validation was performed for tacrolimus and mycophenolic acid by comparison of paired VAMS and venipuncture samples using Passing-Bablok regression and Bland-Altman analysis. Conversion of mycophenolic acid VAMS to serum concentrations was evaluated using haematocrit-dependent formulas and fixed correction factors defined a priori. Patients' perspectives, including useability, acceptability and feasibility, were also investigated using established questionnaires. RESULTS: Paired samples (n = 50) were collected from 25 kidney transplant recipients. Differences for tacrolimus whole-blood concentration were within ±20% for 86 and 88% of samples from the upper arm and fingerstick, respectively. Using correction factors of 1.3 for the upper-arm and 1.47 for finger-prick samples, 84 and 76% of the paired samples, respectively, were within ±20% for mycophenolic acid serum concentration. Patient experience surveys demonstrated limited pain and acceptable useability of the upper-arm device. CONCLUSIONS: Tacrolimus and mycophenolic acid can be measured using 2 common VAMS devices with similar analytical performance. Patients are supportive of home-based monitoring with a preference for the Tasso-M20 device.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Leino AD, Takyi-Williams J, Park JM, et al. Clinical validation of two volumetric absorptive microsampling devices to support home-based therapeutic drug monitoring of immunosuppression. Br J Clin Pharmacol. 2024. PMID: 39051148. doi:10.1111/bcp.16182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。